SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the presentation of results from its second prulifloxacin Phase 3 clinical study for the treatment of infectious diarrhea in travelers, by clinical investigator Robert Steffen, M.D., at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Dr. Steffen presented the positive top-line results that the Company had previously announced in February 2009. The results showed that prulifloxacin met the study objective of superiority to placebo in the resolution of diarrhea, measured by Time to Last Unformed Stool (TLUS) in patients suffering from TD-associated pathogens such as E. coli, Salmonella, Campylobacter, and Shigella. Prulifloxacin showed a statistically significant benefit compared to placebo in TLUS in both the mITT (modified intent- to-treat; n=200) and microbiologically evaluable (per protocol; n=173) populations. The median TLUS for patients treated with prulifloxacin was 32.8 hours; this was significantly different from the TLUS for placebo with a p-value of <0.0001. The Company plans to file a new drug application (NDA) during the first half of next year.
"The high levels of efficacy demonstrated in this study, combined with the convenient dosing schedule, suggest that prulifloxacin has the potential to become a standard treatment for travelers' diarrhea," said Robert Steffen, M.D., primary investigator and head of the Division of Epidemiology and Prevention of Communicable Diseases at the University of Zurich, and Director of the World Health Organization Collaborating Center for Traveler's Health. "While several antibiotic-based treatment options are currently available, many fall short of treating the disease adequately due to limited antibacterial coverage, bacterial resistance and poor patient compliance."
To view the poster on prulifloxacin, please visit the Resources webpage on our website at www.optimerpharma.com.
Prulifloxacin Clinical Study Design
This study, referenced as OPT-099-002, was conducted at sites in India, Guatemala, and Mexico and evaluated adult travelers from industrialized countries suffering from infectious diarrhea. The patients were randomized (1:1) to receive either 600mg of prulifloxacin or placebo, once daily over three days. Stool specimens were collected before treatment and one to three days following the end of treatment to identify intestinal pathogens. The primary efficacy endpoint was Time to the Last Unformed Stool, which was defined as the time in hours from the first dose of study medication to the passage of the last unformed stool.
This is the second of two pivotal Phase 3 clinical studies performed in preparation for filing a new drug application (NDA) with the U.S. Food and Drug Administration (FDA). Data from the first Phase 3 study, referenced as OPT-099-001, was announced in July 2008, and also showed that prulifloxacin met the primary endpoint of TLUS in both the mITT (n=187) and microbiologically evaluable (n=165) populations compared to placebo. The median TLUS for patients treated with prulifloxacin in the first Phase 3 trial was approximately 24 hours, which was significantly different from the median TLUS for placebo with a p-value of <0.0001. The first Phase 3 study was conducted at sites in Mexico and Peru.
Prulifloxacin is a fluoroquinolone pro-drug and is metabolized in the body to the active compound ulifloxacin, which is effective against enteric and non-enteric gram-negative bacilli, major pathogens that cause travelers' diarrhea. It is approved in Japan, Korea and several European countries for the treatment of various bacterial diseases including respiratory and urinary tract infections, skin infections, infectious enteritis, cystitis, and prostatitis. In addition, prulifloxacin maintains high concentrations in the gastrointestinal tract, enabling a more convenient dosing regimen, once daily for 3 days, when compared to other therapies, such as ciprofloxacin, doxycyclene, trimethoprim/sulfamethoxazole, rifaximin and ampicillin. Optimer acquired exclusive rights to discover, develop and commercialize prulifloxacin in the U.S. from Nippon Shinyaku Co., Ltd., in June 2004.
About Infectious Diarrhea
Infectious diarrhea can be caused through infection by bacteria, viruses or parasites. Travelers' diarrhea is infectious diarrhea contracted by the ingestion of contaminated food or water by travelers to a developing country. Symptoms include stomach cramps, vomiting, nausea, fever and headache. Approximately 85% of travelers' diarrhea cases are caused by bacteria, such as E. coli, Shigella, Salmonella, or Campylobacter. The limitations of currently available antibiotics for infectious diarrhea include limited spectrum of activity, antimicrobial resistance, possible side effects, and poor compliance, which can reduce successful outcome.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the efficacy and potential of Prulifloxacin as a treatment of infectious diarrhea, the ability of Prulifloxacin Phase 3 trial results to support an NDA filing and any expected filing of an NDA with respect to Prulifloxacin. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the development of treatments that may compete with Optimer's drug candidates, the potential of negative factors that could arise following a full analysis of clinical trial data, the fact that past clinical results may not be indicative of future clinical results, the timing, progress and likelihood of success of Optimer's product research and development programs, the fact that the FDA may not view Optimer's clinical trial results as sufficient to allow marketing approval for its product candidates, the timing and status of Optimer's preclinical and clinical development of potential drugs and related filings with the FDA, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.
Contacts Optimer Pharmaceuticals, Inc. Christina Donaghy, Corporate Communications Manager John D. Prunty, Chief Financial Officer & VP Finance 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved